Pages Menu
Twitter
Categories Menu

Posted by on Sep 26, 2017 in Neurology, Neuropsychiatry, Pharma

In Alzheimer Phase 3 Development, Yet Another One Bites the Dust

In Alzheimer Phase 3 Development, Yet Another One Bites the Dust

This time it’s Axovant’s 5HT6 antagonist, intepirdine. The drug was intended as a symptomatic add-on therapy to donepezil.

Stat News has the story and the fallout.

bmartin (1130 Posts)

A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on and Twitter.